FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Slideshows|August 11, 2022
5 Clinical Updates in Tick-borne Disease Research
Author(s)Sydney Jennings
Advertisement
Summer is in full swing and Americans are enjoying the outdoors before the cold weather comes back. With warm weather, however, come ticks and tick-borne diseases. What is new in this area of research? In the slides below, find details on 5 key pieces of research in tick-borne diseases, including an investigational Lyme disease vaccine and insight into the spread of Rocky Mountain spotted fever.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Lyme Seropositivity Linked to Tick-Borne Co-Exposure in US Laboratory Study
5